Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Asian Pac J Cancer Prev. 2022 Jun 1;23(6):1847-1858. doi: 10.31557/APJCP.2022.23.6.1847.
Cimetidine and ibuprofen exhibit immunomodulatory effects as an antagonist of histamine H2 receptor, and a cyclooxygenase inhibitor, respectively. Here, the effects of cimetidine and ibuprofen on some effector T cell-related parameters were investigated using a breast cancer (BC) model. BC was established in Balb/c mice using the 4T1 cell line. On day 10 after tumor induction, the BC-bearing mice were classified into four groups and treated with PBS, cimetidine (20 mg/kg), ibuprofen (20 mg/kg) or a combination of "cimetidine + ibuprofen" via intraperitoneal injection (daily from days 11 to 30). The mice were sacrificed on day 31 and the frequency of splenic Th1 and Treg cells, plasma IFN-γ and TGF-β levels, and intra-tumoral T-bet, GATA3, FOXP3 and RORγt expressions were detected using flowcytometry, ELISA and real-time-PCR, respectively. In untreated cancerous mice, the percentage of splenic Th1 cells and plasma IFN-γ levels were lower (P<0.003 and P<0.01, respectively), whereas the percentage of splenic Treg cells and plasma TGF-β levels were higher than in healthy mice (P<0.04 and P<0.005, respectively). Treatment of BC-bearing mice with cimetidine, ibuprofen or both drugs promoted the frequency of Th1 cells (P<0.05, P<0.007 and P<0.005, respectively) as well as IFN-γ levels (P<0.004, P<0.0001 and P<0.03, respectively), while reduced the frequencies of Treg cells (P<0.02, P<0.03 and P<0.01, respectively), TGF-β levels (P<0.006, P<0.02 and P<0.002, respectively), intra-tumoral expression of FOXP3 (P<0.006, P<0.005 and P<0.005, respectively), and intra-tumoral expression of RORγt (P<0.04, P<0.03 and P<0.05, respectively) compared with untreated BC mice. The "cimetidine + ibuprofen"-treated mice displayed greater T-bet expression than the un-treated mice (P<0.006). Cimetidine and/or ibuprofen-treated BC-bearing mice exhibited reduced intra-tumoral expression of GATA3 compared with the untreated BC mice, but the differences were not significant. Cimetidine and ibuprofen correct some effector T cell-related parameters in cancerous mice. Immunotherapeutic potentials cimetidine and ibuprofen in cancers need investigations.
西咪替丁和布洛芬分别作为组胺 H2 受体拮抗剂和环氧化酶抑制剂,具有免疫调节作用。在这里,我们使用乳腺癌(BC)模型研究了西咪替丁和布洛芬对一些效应 T 细胞相关参数的影响。使用 4T1 细胞系在 Balb/c 小鼠中建立 BC。在肿瘤诱导后第 10 天,将荷瘤小鼠分为四组,并用 PBS、西咪替丁(20mg/kg)、布洛芬(20mg/kg)或“西咪替丁+布洛芬”组合通过腹腔注射(从第 11 天到第 30 天每天一次)进行治疗。第 31 天处死小鼠,通过流式细胞术、ELISA 和实时-PCR 分别检测脾 Th1 和 Treg 细胞的频率、血浆 IFN-γ 和 TGF-β 水平以及肿瘤内 T-bet、GATA3、FOXP3 和 RORγt 的表达。在未治疗的癌症小鼠中,脾 Th1 细胞的百分比和血浆 IFN-γ 水平较低(P<0.003 和 P<0.01,分别),而脾 Treg 细胞的百分比和血浆 TGF-β 水平高于健康小鼠(P<0.04 和 P<0.005,分别)。用西咪替丁、布洛芬或两种药物治疗荷瘤小鼠可促进 Th1 细胞的频率(P<0.05、P<0.007 和 P<0.005,分别)以及 IFN-γ 水平(P<0.004、P<0.0001 和 P<0.03,分别),同时降低 Treg 细胞的频率(P<0.02、P<0.03 和 P<0.01,分别)、TGF-β 水平(P<0.006、P<0.02 和 P<0.002,分别)、肿瘤内 FOXP3 的表达(P<0.006、P<0.005 和 P<0.005,分别)和肿瘤内 RORγt 的表达(P<0.04、P<0.03 和 P<0.05,分别)与未治疗的 BC 小鼠相比。与未治疗的 BC 小鼠相比,“西咪替丁+布洛芬”治疗的小鼠 T-bet 表达更高(P<0.006)。用西咪替丁和/或布洛芬治疗荷瘤 BC 小鼠的肿瘤内 GATA3 表达低于未治疗的 BC 小鼠,但差异无统计学意义。西咪替丁和布洛芬可纠正癌症小鼠的一些效应 T 细胞相关参数。西咪替丁和布洛芬在癌症中的免疫治疗潜力需要进一步研究。